e-learning
resources
Amsterdam 2011
Wednesday, 28.09.2011
Clinical approach of diffuse parenchymal lung disease
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Physiology is a better predictor of mortality than HRTC findings in patients with fibrotic idiopathic interstitial pneumonia
F. Novelli, L. Tavanti, F. Martino, S. Cini, L. Melosini, C. Romei, F. Falaschi, S. Solfanelli, A. Celi, P. Paggiaro (Pisa, Italy)
Source:
Annual Congress 2011 - Clinical approach of diffuse parenchymal lung disease
Session:
Clinical approach of diffuse parenchymal lung disease
Session type:
Oral Presentation
Number:
4859
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
F. Novelli, L. Tavanti, F. Martino, S. Cini, L. Melosini, C. Romei, F. Falaschi, S. Solfanelli, A. Celi, P. Paggiaro (Pisa, Italy). Physiology is a better predictor of mortality than HRTC findings in patients with fibrotic idiopathic interstitial pneumonia. Eur Respir J 2011; 38: Suppl. 55, 4859
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
From pulmonary gas exchange to the interpretation of arterial blood gases
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Related content which might interest you:
High short-term mortality following lung biopsy for usual interstitial pneumonia
Source: Eur Respir J 2001; 17: 175-179
Year: 2001
Survival after respiratory hospitalization in patients with idiopathic chronic fibrosing interstitial pneumonia
Source: International Congress 2018 – What is new in idiopathic interstitial pneumonias?
Year: 2018
Predictors of survival in idiopathic interstitial pneumonia
Source: Annual Congress 2007 - Considerations in the management of idiopathic pulmonary fibrosis and other interstitial lung diseases
Year: 2007
A large cohort study of clinical outcomes and prognostic predictors in patients with acute exacerbation of idiopathic pulmonary fibrosis
Source: International Congress 2014 – IPF and surroundings
Year: 2014
Survival of patients with biopsy-proven usual interstitial pneumonia and nonspecific interstitial pneumonia
Source: Eur Respir J 2002; 19: 1114-1118
Year: 2002
Biopsy documented idiopathic interstitial pneumonias - Analysis of diagnostic yield, survival and mortality over 9 years
Source: Annual Congress 2013 –Interventional procedures for diagnosis of diffuse lung diseases and peripheral pulmonary lesions
Year: 2013
Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study
Source: Eur Respir J 2012; 40: 101-109
Year: 2012
Difference of the clinical characteristics and outcome between interstitial lung disease with dermatomyositis and idiopathic interstitial pneumonia
Source: International Congress 2017 – Lung function testing
Year: 2017
Outcome of patients with interstitial lung disease admitted into ICU
Source: Annual Congress 2011 - Clinical approach of diffuse parenchymal lung disease
Year: 2011
Clinical significance of histological classification of idiopathic interstitial pneumonia
Source: Eur Respir J 2002; 19: 275-283
Year: 2002
Predictor factors of mortality in patients with idiopathic pulmonary fibrosis
Source: International Congress 2018 – Idiopathic interstital pneumonias other than idiopathic pulmonary fibrosis (IPF)
Year: 2018
Quantifying risk of mortality in idiopathic interstitial pneumonia (IIP)
Source: Eur Respir J 2001; 18: Suppl. 33, 149s
Year: 2001
Respiratory comorbidities and risk of mortality in hospitalized patients with idiopathic pulmonary fibrosis.
Source: International Congress 2017 – ILDs: clinical aspects
Year: 2017
Recent improvement of survival of acute exacerbation in idiopathic interstitial pneumonias: 10 years experience
Source: International Congress 2014 – ILDs 2
Year: 2014
Clinical experience with nintedanib for the treatment of IPF in 80 cases
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016
Prognostic evaluation of idiopathic interstitial pneumonia: emerging data
Source: Research Seminar 2010 - Novel insights in pulmonary fibrogenesis: from bench to bedside Research Seminar
Year: 2010
Clinical impact of an interstitial lung disease Nurse on patients with idiopathic pulmonary fibrosis
Source: International Congress 2018 – What is new in idiopathic interstitial pneumonias?
Year: 2018
Comparison of densitometric and visual scoring in the assessment of severity of idiopathic fibrotic interstitial pneumonias: Preliminary observations
Source: International Congress 2015 – New insights into IIPs
Year: 2015
Recurrence predictive factors of cryptogenic organizing pneumonia
Source: International Congress 2015 – Connective tissue disorders
Year: 2015
Acute exacerbation of idiopathic pulmonary fibrosis as the initial presentation of the disease
Source: Eur Respir Rev 2009; 18: 129-132
Year: 2009
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept